Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Avid Bioservices, Inc. CDMO
$17.25
-$0.38 (-2.21%)
На 18:00, 12 мая 2023
Ранг: 2
Ключевые показатели
-
Marketcap
1102705373.00000000
-
week52high
21.05
-
week52low
11.30
-
Revenue
119597000
-
P/E TTM
10
-
Beta
1.82352900
-
EPS
1.64000000
-
Last Dividend
0.65600000
-
Next Earnings Date
27 июн 2023 г. в 10:59
Описание компании
Avid Bioservices, Inc., a contract development and manufacturing organization, provides process development and current good manufacturing practices (CGMP) clinical and commercial manufacturing services focused on biopharmaceutical drug substances derived from mammalian cell culture. The company produces monoclonal antibodies and recombinant proteins; and offers services, including CGMP clinical and commercial drug substance manufacturing, bulk packaging, release and stability testing, and regulatory submission and support. It also provides various process development services, such as upstream and downstream development and optimization, analytical methods development, testing, and characterization. The company serves biotechnology and biopharmaceutical industries. The company was formerly known as Peregrine Pharmaceuticals, Inc. and changed its name to Avid Bioservices, Inc. in January 2018. Avid Bioservices, Inc. was incorporated in 1981 and is headquartered in Tustin, California.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| RBC Capital | Outperform | Outperform | 30 июн 2022 г. |
| Stephens & Co. | Overweight | Overweight | 09 мар 2022 г. |
| RBC Capital | Outperform | Outperform | 08 дек 2021 г. |
| Keybanc | Sector Weight | Overweight | 08 дек 2021 г. |
| Craig-Hallum | Buy | Buy | 08 дек 2021 г. |
| RBC Capital | Outperform | Outperform | 07 дек 2022 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Hancock Richard B | D | 193266 | 5000 | 01 февр 2023 г. |
| Hancock Richard B | D | 39134 | 5000 | 01 февр 2023 г. |
| Hancock Richard B | A | 44134 | 5000 | 01 февр 2023 г. |
| Alegria Esther M. | D | 0 | 5321 | 13 янв 2023 г. |
| Hancock Richard B | D | 198266 | 986 | 12 янв 2023 г. |
| Hancock Richard B | D | 199252 | 1635 | 12 янв 2023 г. |
| Hancock Richard B | D | 39134 | 986 | 12 янв 2023 г. |
| Hancock Richard B | A | 40120 | 986 | 12 янв 2023 г. |
| Hancock Richard B | A | 40769 | 1635 | 12 янв 2023 г. |
| Hart Daniel R | D | 49957 | 1499 | 10 янв 2023 г. |
Новостная лента
Monoclonal Antibodies? Avid Bioservices surges 32% on Blowout Q3
MarketBeat
14 мар 2023 г. в 13:12
Avid Bioservices Inc. (NASDAQ: CDMO) is a contract development and manufacturing organization (CDMO) that specializes in producing monoclonal antibodies, biologics, and novel proteins for biotech, healthcare, and pharmaceutical companies. Monoclonal antibodies were a hot topic of discussion during the pandemic.
Why Avid Bioservices Stock Is Surging Today
The Motley Fool
14 мар 2023 г. в 12:35
Avid Bioservices' fiscal 2023 third-quarter earnings report painted an encouraging picture. Even so, the biotech's stock may be close to fair value after today's double-digit move higher.
CDMO Stock: 10.85% Increase After Hours Explanation
Pulse2
13 мар 2023 г. в 22:42
The stock price of Avid Bioservices Inc (NASDAQ: CDMO) increased by 10.85% after hours in the most recent trading session. This is why.
Avid Bioservices, Inc. (CDMO) Q3 2023 Earnings Call Transcript
Seeking Alpha
13 мар 2023 г. в 21:46
Avid Bioservices, Inc. (NASDAQ:CDMO ) Q3 2023 Earnings Conference Call March 13, 2023 4:30 PM ET Company Participants Tim Brons - Investor Relations Nick Green - President and Chief Executive Officer Dan Hart - Chief Financial Officer Matt Kwietniak - Chief Commercial Officer Conference Call Participants Sean Dodge - RBC Capital Markets Matt Hewitt - Craig-Hallum Jacob Johnson - Stephens Paul Knight - KeyBanc Operator Good day, ladies and gentlemen and welcome to the Avid Bioservices Third Quarter Fiscal 2023 Financial Results Conference Call. [Operator Instructions] As a reminder, this conference call maybe recorded.
Avid Bioservices (CDMO) Q3 Earnings and Revenues Top Estimates
Zacks Investment Research
13 мар 2023 г. в 19:07
Avid Bioservices (CDMO) delivered earnings and revenue surprises of 275% and 5.61%, respectively, for the quarter ended January 2023. Do the numbers hold clues to what lies ahead for the stock?